{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:06:18Z","timestamp":1792760778405,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 has shown promise for urothelial cancer (UC) detection. This study evaluates its diagnostic value versus contrast-enhanced CT (ceCT) and 2-[\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET in the largest bi-centric cohort to date.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with metastatic UC undergoing [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET at University Hospitals Munich or Essen were retrospectively reviewed. Detection rates were compared with ceCT on a regional basis (primary, lymph nodes, visceral organs, bone). SUV\n                      <jats:sub>max<\/jats:sub>\n                      and SUV\n                      <jats:sub>mean<\/jats:sub>\n                      of two index lesions were recorded. In a sub-cohort, [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 and 2-[\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET were compared on a lesion basis. Clinical follow-up and\/or histopathology served as reference.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-four patients underwent [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET\/CT and ceCT, including 10 (29%) with additional 2-[\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT. Across 98 lesions (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200965 regions), [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET detected\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200996 (98%) and ceCT\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200988 (90%), with mismatch findings in eight lymph nodes (PET positive\/ceCT negative) and two visceral organs (ceCT positive\/PET negative). In the subgroup comparison, 78 lesions were detected in total ([\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200972 (92%); 2-[\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200978 (100%)). Tumour uptake was comparable (SUV\n                      <jats:sub>max<\/jats:sub>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET vs. 2-[\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG: 10.2 (IQR, 1.9) vs. 8.0 (IQR, 3.3),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.249), whereas [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 provided higher tumour-to-background ratios (Tumour-to-liver: 12.7 (IQR, 10.3) vs. 3.8 (IQR, 1.9),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046; tumour-to-spleen: 8.4 (IQR, 6.6) vs. 4.6 (IQR, 0.6),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET demonstrated higher regional detection rates than ceCT in UC patients, particularly for lymph node metastases. Compared to 2-[\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG, it provided superior tumour-to-background contrast but detected slightly fewer lesions. [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET may complement established imaging in selected scenarios, although its role in routine UC staging remains investigational.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07674-5","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:12:29Z","timestamp":1764054749000},"page":"3162-3171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-0795","authenticated-orcid":false,"given":"Kim M.","family":"Pabst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie C.","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans P.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Bartel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina T.","family":"K\u00fcper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Aydogdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris A.","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"7674_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:244\u201358.","journal-title":"Ann Oncol"},{"key":"7674_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/ije\/dyw044","volume":"45","author":"FH van Osch","year":"2016","unstructured":"van Osch FH, Jochems SH, van Schooten FJ, et al. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol. 2016;45:857\u201370.","journal-title":"Int J Epidemiol"},{"key":"7674_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79:62\u201379.","journal-title":"Eur Urol"},{"issue":"5","key":"7674_CR4","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.eururo.2012.01.049","volume":"61","author":"TV Tarin","year":"2012","unstructured":"Tarin TV, Power NE, Ehdaie B, et al. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol. 2012;61(5):1025\u201330.","journal-title":"Eur Urol"},{"key":"7674_CR5","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","volume":"176","author":"SF Shariat","year":"2006","unstructured":"Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. J Urol. 2006;176:2414\u201322.","journal-title":"J Urol"},{"key":"7674_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.eururo.2012.06.008","volume":"63","author":"SF Shariat","year":"2013","unstructured":"Shariat SF, Rink M, Ehdaie B, et al. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. Eur Urol. 2013;63:371\u20138.","journal-title":"Eur Urol"},{"issue":"1","key":"7674_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eururo.2006.05.021","volume":"51","author":"SF Shariat","year":"2007","unstructured":"Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007;51(1):137\u201351.","journal-title":"Eur Urol"},{"key":"7674_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00345-018-2439-8","volume":"37","author":"J Crozier","year":"2019","unstructured":"Crozier J, Papa N, Perera M, et al. Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World J Urol. 2019;37:667\u201390.","journal-title":"World J Urol"},{"key":"7674_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.eururo.2009.05.014","volume":"57","author":"G Swinnen","year":"2010","unstructured":"Swinnen G, Maes A, Pottel H, et al. FDG-PET\/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57:641\u20137.","journal-title":"Eur Urol"},{"key":"7674_CR10","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.3390\/cancers13194946","volume":"30","author":"K Dendl","year":"2021","unstructured":"Dendl K, Koerber SA, Kratochwil C, et al. FAP and FAPI-PET\/CT in malignant and Non-Malignant diseases: A perfect symbiosis? Cancers (Basel). 2021;30:4946.","journal-title":"Cancers (Basel)"},{"key":"7674_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.humpath.2019.07.002","volume":"91","author":"J Calvete","year":"2019","unstructured":"Calvete J, Larrinaga G, Errarte P, et al. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5\/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Hum Pathol. 2019;91:61\u20138.","journal-title":"Hum Pathol"},{"key":"7674_CR12","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00259-022-05761-5","volume":"49","author":"LM Unterrainer","year":"2022","unstructured":"Unterrainer LM, Lindner S, Eismannn L, et al. Feasibility of [68Ga]Ga-FAPI-46 PET\/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. Eur J Nucl Med Mol Imaging. 2022;49:3571\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7674_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","volume":"24","author":"E Novruzov","year":"2022","unstructured":"Novruzov E, Dendl K, Ndlovu H, et al. Head-to-head intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in patients with bladder cancer. Mol Imaging Biol. 2022;24:651\u20138.","journal-title":"Mol Imaging Biol"},{"key":"7674_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2967\/jnumed.123.266390","volume":"65","author":"VS Koshkin","year":"2024","unstructured":"Koshkin VS, Kumar V, Kline B, et al. Initial experience with 68Ga-FAP-2286 PET imaging in patients with urothelial cancer. J Nucl Med. 2024;65:199\u2013205.","journal-title":"J Nucl Med"},{"issue":"1","key":"7674_CR15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3917\/jib.151.0124","volume":"15","author":"Assembly, World Medical Association General","year":"2004","unstructured":"Assembly, World Medical Association General. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. J Int De bioethique = Int J Bioeth. 2004;15(1):124\u20139.","journal-title":"J Int De bioethique = Int J Bioeth"},{"key":"7674_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nucmedbio.2022.04.010","volume":"110\u2013111","author":"M Nader","year":"2022","unstructured":"Nader M, Valla DF, Vriamont C, et al. [68Ga]\/[90Y]FAPI-46: automated production and analytical validation of a theranostic pair. Nucl Med Biol. 2022;110\u2013111:37\u201344.","journal-title":"Nucl Med Biol"},{"issue":"2","key":"7674_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5603\/NMR.2014.0022","volume":"17","author":"A d\u2019Amico","year":"2014","unstructured":"d\u2019Amico A, Gorczewska I, Gorczewski K, Turska-d\u2019Amico M, Di Pietro M. Effect of furosemide administration before F-18 fluorodeoxyglucose positron emission tomography\/computed tomography on urine radioactivity and detection of uterine cervical cancer. Nucl Med Rev Cent East Eur. 2014;17(2):83\u20136.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"7674_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG-PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7674_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.eururo.2015.12.051","volume":"70","author":"A Herlemann","year":"2016","unstructured":"Herlemann A, Wenter V, Kretschmer A, et al. (68)Ga-PSMA positron emission tomography\/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70(4):553\u20137.","journal-title":"Eur Urol"},{"issue":"7","key":"7674_CR20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2967\/jnumed.122.265245","volume":"64","author":"R Mei","year":"2023","unstructured":"Mei R, Kessler L, Pabst KM, et al. 68Ga-FAPI PET\/CT interobserver agreement on tumor assessment: an international multicenter prospective study. J Nucl Med. 2023;64(7):1043\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"7674_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","volume":"52","author":"KM Pabst","year":"2024","unstructured":"Pabst KM, Mei R, L\u00fcckerath K, et al. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-\/[18F]F-PSMA-11\/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET\/CT: a pilot study. Eur J Nucl Med Mol Imaging. 2024;52(1):342\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"7674_CR22","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","volume":"48","author":"M Sollini","year":"2021","unstructured":"Sollini M, Kirienko M, Gelardi F, et al. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4396\u2013414.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7674_CR23","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2967\/jnumed.122.264069","volume":"63","author":"FM Glatting","year":"2022","unstructured":"Glatting FM, Hoppner J, Liew DP, et al. Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-75: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions. J Nucl Med. 2022;63(12):1844\u201351.","journal-title":"J Nucl Med"},{"issue":"12","key":"7674_CR24","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.2967\/jnumed.123.265751","volume":"64","author":"TT Demmert","year":"2023","unstructured":"Demmert TT, Pomykala KL, Lanzafame H, et al. Oncologic staging with 68Ga-FAPI PET\/CT demonstrates a lower rate of nonspecific lymph node findings than 18F-FDG PET\/CT. J Nucl Med. 2023;64(12):1906\u20139.","journal-title":"J Nucl Med"},{"key":"7674_CR25","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00259-024-06669-y","volume":"51","author":"Yk Kang","year":"2024","unstructured":"Kang Yk, Na KJ, Park J, et al. Preoperative evaluation of mediastinal lymph nodes in non-small cell lung cancer using [68Ga]FAPI-46 PET\/CT a prospective pilot study. Eur J Nucl Med Mol Imaging. 2024;51:2409\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7674_CR26","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, et al. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61(8):1171\u20137.","journal-title":"J Nucl Med"},{"issue":"suppl 2","key":"7674_CR27","volume":"63","author":"N Hasani","year":"2022","unstructured":"Hasani N, Farhadi F, Saboury B, Morris M, Beegle C. Rediscovering the indispensable role of FDG PET in kidney cancer imaging. J Nucl Med. 2022;63(suppl 2):2695.","journal-title":"J Nucl Med"},{"key":"7674_CR28","unstructured":"Watabe T, Naka S, Tatsumi M et al. Evaluation of physiological biliary excretion patterns in [18F]FAPI-74 PET. J Nucl Med 2024; 65(suppl. 2):241515."},{"key":"7674_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.123.266403","volume":"65","author":"Y Miao","year":"2024","unstructured":"Miao Y, Feng R, Yu T, et al. Value of 68Ga-FAPI-04 and 18F-FDG PET\/CT in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer. J Nucl Med. 2024;65:213\u201320.","journal-title":"J Nucl Med"},{"key":"7674_CR30","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1007\/s00259-023-06271-8","volume":"50","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Cheng K, Yun Z. [18F] AlF-NOTA-FAPI-04 PET\/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2023;50:3425\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7674_CR31","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00259-021-05266-7","volume":"48","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus J, Kessler L, Hirmas N, et al. Equivalent tumor detection for early and late FAPI-46 PET acquisition. Eur J Nucl Med Mol Imaging. 2021;48(10):3221\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07674-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07674-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07674-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:04Z","timestamp":1774401964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07674-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7674"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07674-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KMP was supported by the Clinician Scientist Program of the University Medicine Essen Clinician Scientist Academy (UMEA; Faculty of Medicine and Deutsche Forschungsgemeinschaft [DFG]); consulting fees: Novartis, GE Healthcare; travel fees: Novartis, IPSEN; research funding: Bayer; membership of the ESHI\n                      MT\n                      (European Society for Hybrid, Molecular and Translational Imaging) Research Committee; all outside the submitted work.\u00a0AH: membership of the ESHI\n                      MT\n                      \u00a0(European\u00a0Society for Hybrid, Molecular and Translational Imaging) Research Committee; all outside the\u00a0submitted work.\u00a0TB: travel fees: PARI GmbH; all outside the submitted work\u00a0KH: personal fees:\u00a0Bayer, SOFIE Bioscience, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Healthineers, GE\u00a0Healthcare, Amgen, Novartis, ymabs, Aktis, Oncology, Pharma15; non-financial support: ABX;\u00a0grants\/personal fees: BTG; all outside the submitted work. DK reports speaker honoraria from\u00a0Pfizer and Novartis, a research grant from Pfizer, and funding by the German Research\u00a0Foundation (DFG, KE2933\/1-1); all outside the submitted work. CK: Research Funding: Novartis,\u00a0Amgen, Mariana Oncology; Honoraria: Novartis, Pfizer; Travel support: Pfizer, Bayer, Amgen; all\u00a0outside the submitted work. BAH: Grants: DFG, Novartis, BMS, Janssen, Amgen; Royalties or\u00a0licences: Uromed; consultant: Janssen, Bayer, Novartis, BMS, ABX, Merck, Onkowissen, Accord\u00a0Healthcare, AstraZeneca, MSD\/Pfizer, Amgen, Astellas, Lightpoint medical, Point Biopharma,\u00a0Ipsen, Telix; Honoraria: Janssen, Amgen, Astellas, Monrol, Novartis; Travel fees: Janssen,\u00a0AstraZeneca, Bayer, BMS, Ipsen, Amgen, Participation on a Data Safety Monitoring Board or\u00a0Advisory Board: Janssen, ABX, Telix; Leadership or fiduciary role in societies: DGU; all outside\u00a0the submitted work. RAW: speaker honoraria from Novartis\/AAA and PentixaPharm, advisory\u00a0board work for Novartis\/AAA and Bayer; outside the submitted work. WPF: fees from SOFIE\u00a0Bioscience (research funding), Janssen (consultant, speaker), Perceptive (consultant, image\u00a0review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix\u00a0(speaker), GE Healthcare (speaker, consultant), Eczac\u0131ba\u015f\u0131 Monrol (speaker), Abx (speaker),\u00a0Amgen (speaker), Urotrials (speaker), Lilly (consultant), AstraZeneca (research funding); all\u00a0outside the submitted work. LMU: funding: Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF)\u00a0and from the Munich Clinician Scientist Program (MCSP). She reports fees from Novartis\u00a0(speaker), Telix (consultant) and Astellas Pharma Inc. (speaker); chair of the ESHI\n                      MT\n                      \u00a0(European\u00a0Society for Hybrid, Molecular and Translational Imaging) Research Committee; all outside of the\u00a0submitted work. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This analysis was conducted in accordance with the Declaration of Helsinki and its subsequent amendments and approved by the respective institutional ethics committees at LMU University Hospital Munich (IRB 24\u20130255) and University Hospital Essen (20-9485-BO\/20-9777-BO).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      ,\n                      \n                      ,\n                      \n                      and\n                      \n                      and Suppl. Figure\u00a0\n                      \n                      .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}